Atlas Trials

Study of the Safety and Efficacy of the Subunit Recombinant Tuberculosis Vaccine GamTBvac

Clinical trial NCT04975737 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04975737
Sponsor
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Tuberculosis
Start date
2022-01-20
Primary completion
2026-12-01
Enrollment
9500

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.